China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair
HARBIN, China, Dec. 27, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines ("TCM") in China, today announced that the Company successfully showcased its all-natural products at the 66th PHARMCHINA fair ("the Fair") recently held in Zhengzhou, China.
China Botanic's all-natural and plant based remedies attracted significant attention and interest from manufacturers, distributors, and other attendees at the Fair. The Company was focused on increasing knowledge and awareness of its all natural products which are beneficial in treatment and prevention of depression. Over 20 distributors expressed strong interest in the Company's anti-depressant products and are seeking to engage in further discussion on potential partnerships. Management estimates an approximate revenue contribution of RMB5 million (or approximately $0.8 million) in fiscal year 2012 from the business generated at the fair compared to the contribution of $0.6million from last year's fair.
"PHARMCHINA is China's largest pharmaceutical fair which attracts attendees from all over the country, providing an ideal platform to promote our products and brand," said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "Our focus on the anti-depressant segment reflects the growing customer demand for effective anti-depressant remedies. An estimated 30 million people in China suffer from depression, and yet China has only in recent years listed depression as a disease. We are pleased with the increased awareness we created and the response we received at the fair this year. We will continue to participate in similar events to build disease awareness and long-term brand recognition of our products. At the same time, we continue to grow our business organically and enhance our overall operational efficiency."
PHARMCHINA is the largest exhibition in China's pharmaceutical industry. With a history of over 30 years, the PHARMCHINA fair covers an area of approximately 70,000 square meters and attracts over 2,800 exhibitors and 120,000 visitors. Twice a year, exhibitors and visitors attend PHARMCHINA for new business opportunities in the rapidly developing China's pharmaceutical market, including chemical-based drugs, TCM, bio-pharmaceuticals, OTC medicine, health care products, cosmetics, and healthcare-related technologies and other services. For more information, please visit http://en.pharmchina.com.cn/.
ABOUT CHINA BOTANIC PHARMACEUTICAL INC.
China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
CCG Investor Relations:
China Botanic Pharmaceutical Inc.
Mr. Mark Collinson, Partner
Ms. Portia Tan, IR Contact
Phone: +1-310-954-1343 (Los Angeles)
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
SOURCE China Botanic Pharmaceutical Inc.
Web Site: http://en.pharmchina.com.cn/
Posted: December 2011